This is Archived Content

This content is available for historical purposes only. It may not reflect the current state of science or language from the National Institute on Drug Abuse (NIDA). Find the latest information on substance use, health, and NIDA research at

Cite this article

NIDA. (2017, May 8). Smoking cessation medications alleviate symptoms of nicotine withdrawal, but not long-term brain changes. Retrieved from

press ctrl+c to copy

Science Highlight

May 08, 2017
Cigarette endsPhoto by © M Lee

Researchers now report that nicotine replacement therapy and the smoking cessation medication varenicline alleviate ex-smokers’ deficits in decision-making, but do not restore reward sensitivity. The new study pinpoints the types of decision errors newly abstinent smokers make, and how their brain activity during decision-making differs from that of non-smokers.

The researchers note that impulsivity is a feature of acute withdrawal from nicotine. Depressed reward sensitivity, in contrast, reflects the severity of a smoker’s dependence on the drug. Over time, the brain naturally recoups reward sensitivity. Meanwhile, however, the abstinent smoker may be hampered in attempts to find pleasure in healthy alternative activities to smoking.